KSEA

Our patented Kinase Substrate Enrichment Analysis (KSEA) can be used to provide a direct readout of kinase cell-signalling pathway activity in healthy or diseased cells. With our analytical computational algorithms, we can inform and guide drug discovery and development.

scientist in a white coat examing informtion on a clip board scientist stood in a lab wearing a white coat examining data on a clip board
KSea diagram showing edge enrichment in growth factor-treated cells

KSEA (Kinase Substrate Enrichment Analysis) uses data science algorithms, trained on experimental data, to highlight changes in kinases activities as a result of drug or other external perturbations. Applications range from elucidating drug mode of action to the identification of the most effective drug targets.

The Solution: KScan®

KScan®: A next generation biomarker and molecular diagnostics platform

What is KScan®?

A patented database of kinase substrate relationships

Patented algorithms to determine which kinases are enriched

Kinase Activity Leader Board - K-Score

Patented Method for systematic identification of regulatory protein kinases (K-Score)

Significance of KScan®

KScan phosphoproteomics platform

KSEA Publication

Take a look at our library of publications and presentations that cover the topic of our KSEA technology in more detail.

Technologies

Find out more about Kinomica’s powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods

KScan phosphoproteomics platform
scientist in a white coat looking at a laptop male scientist wearing a white coat looking at a laptop screen

Kinomica News

Learn more about Kinomica, our team and our technology through our in-depth blog content. We’ll also let you know what events we are attending as well. 

Talk to our Experts

To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.

Contact Us

If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.

“Our technology can look at over 10,000 proteins in one simple experiment and tell researchers exactly which proteins are activated and deactivated. This is hugely important and relevant for personalised medicine“

Jane Theaker, Kinomica CEO